NEW YORK (Reuters Health) Oct 14 –
In men with advanced prostate cancer, classifying bone scans according to the metastatic site has prognostic value, according to a report published in the October issue of The Journal of Urology.
Dr. Jerome Rigaud and colleagues, from CHU Hotel Dieu in Nantes, France, assessed the outcomes of 86 patients with prostate cancer metastatic to bone who had received primary androgen deprivation therapy. All of the patients underwent bone scanning and were divided into two groups based on whether the metastases involved the axial or appendicular skeleton.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!